April 20, 2016
Research shines new light on malignant hyperthermia
The rare but very serious condition of malignant hyperthermia (MH) remains a risk at all surgical facilities, including ambulatory surgical centers (ASCs). MH occurs in about one in 50,000 adults under anesthesia, and one in about 12,000 children, which translates to one or two deaths annually in the United States. When it does strike, MH often is fatal if not treated within minutes. And the only antidote is a very expensive drug.
Free Daily News
- GLP-1 labels carry pulmonary aspiration warning
- Research reveals racial disparity in postoperative pain management
- Study: Single-syringe pump reduces OR propofol waste
- Study: Delaying elective surgery after myocardial infarction reduces complications in older patients
- Global study dispels benefits of blood pressure management during non-cardiac surgery
- Upcoming webinar covers 6 key metrics to improve OR capacity
- Third-party vendors drive healthcare cybersecurity risks
- New guidance: Preoperative GLP-1s safe for surgical patients
- Study: Beta-blockers could increase postoperative stroke risk
- Music therapy reduces opioid use, anxiety in surgical patients
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement